Table 2.

Adverse events of the study group

System	Side effect	Grade 1/2	Grade 3/4	Total
Overall				42 (89%)
Constitutional	Fatigue	18 (38.3%)	6 (12.8%)	24 (51.1%)
	Weight loss	3 (6.4%)		3 (6.4%)
	Anorexia	3 (6.4%)	1 (2.1%)	4 (8.5%)
Gastrointestinal	Dysguesia	2 (4.3%)		2 (4.3%)
	Nausea	7 (14.9%)		7 (14.9%)
	Vomiting	1 (2.1%)		1 (2.1%)
	Diarrhoea	17 (36.2%)	3 (6.4%)	20 (42.6%)
	Variceal bleeding	2 (4.3%)		2 (4.3%)
	Lower extremity oedema	1 (2.1%)		1 (2.1%)
	Abdominal pain	8 (17%)	3 (6.4%)	11 (23.4%)
	Nonvariceal bleeding	2 (4.3%)	2 (4.1%	4 (8.5%)
	Hypoalbuminaemia	1 (2.1%)	1 (2.1%)	2 (4.3%)
	Pancreatitis	2 (4.3%)		2 (4.3%)
Hepatobiliary (Cirrhosis Sequelae)	Ascites (new)	7 (14.9%)	4 (8.5%)	11 (23%)
	Ascites (worsening)	3 (6.4%)	2 (4.3%)	5 (10.6%)
	Encephalopathy (new)	3 (6.4%)	1 (2.1%)	4 (8.5%)
	Encephalopathy (worsening)	1 (2.1%)		1 (2.1%)
	Lower extremity oedema	1 (2.1%)		1 (2.1%)
	Transamnitis (over baseline)		1 (2.1%)	1 (2.1%)
	INR elevation (over baseline)	1 (2.1%)		1 (2.1%)
	Increase in bilirubin	3 (6.4%)	3 (6.4%)	6 (12.8%)
	Hypoalbuminaemia	1 (2.1%)	1 (2.1%)	2 (4.3%)
Dermatologic	Hand-foot reaction	12 (25.5%)	12 (25.5%)	24 (51.1%)
	Truncal rash	7 (14.9%)		7 (14.9%)
	Facial rash	1 (2.1%)		1 (2.1%)
	Scalp rash	2 (4.3%)		2 (4.3%)
	Alopecia	2 (4.3%)		2 (4.3%)
Cardiovascular	Hypertension		9 (19.3%)	9 (19.2%)
	Hypotension		3 (6.4%)	3 (6.4%)
Haematological	Leucopenia	1 (2.1%)	4 (8.5%)	5 (10.6%)
Electrolyte abnormalities	Hyponatraemia		1 (2.1%)	1 (2.1%)
	Hypokalaemia	1 (2.1%)		1 (2.1%)
	Hypophosphataemia	1 (2.1%)		1 (2.1%)
	Hypomagnesaemia	2 (4.3%)		2 (4.3%)